Novel Druggable Targets in Neuroinflammation and Neuroimmunity

Servier, a leading international pharmaceutical company, seeks novel therapeutic proposals targeting neuroinflammation and/or neuroimmunity in central nervous system and/or peripheral nervous system diseases. They are particularly interested in approaches with identified targets that can counteract these pathological conditions with well-supported pharmacological strategies.

Approaches of interest

• Treatments for ALS (sporadic and genetic forms), autoimmune myasthenia gravis, chronic inflammatory demyelinating polyneuropathies are prioritized, with other neuroinflammatory/neuroimmune diseases considered
• Drug repurposing opportunities with demonstrated proof of concept
• Small molecules, antibodies, and antisense oligonucleotides
   

Out of scope:

• Cell therapy, gene therapy, and medical devices
• Broad or non-targeted anti-inflammatory approaches
  
  Developmental stage of interest: Opportunities up to late preclinical stage with clear proof of concept (at least in vitro). Priority given to opportunities with in vivoproof of concept.

Email Cameron Sargent, CTTC Licensing Officer, at cameron.sargent@vanderbilt.edu for more information.

Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.